Arsanis, Inc.'s President and CEO just picked up 181,366 shares

Paula Ragan, Arsanis, Inc.'s President and CEO and a director of the company, recently acquired 181,366 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on March 13, 2019. Ragan now owns 181,366 shares of the company. Ragan operates out of Cambridge, MA. Some additional info was provided as follows:

Received in exchange for 1,870,000 shares of common stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") and 38,451 shares of Series Seed preferred stock of X4 in connection with the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 (the "Merger") on March 13, 2019. Fully vested. Reflects the Reporting Person's stock option to acqu ire 1,059,935 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger. Twenty-five percent (25%) of the shares subject to the option vested on January 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Reflects the Reporting Person's stock option to acquire 688,500 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger. Twenty-five percent (25%) of the shares subject to the option vested on January 31, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Reflects the Reporting Person's stock option to acquire 843,496 shares of X4 common stock for $0.67 per share that was assumed by the Issuer in the Merger.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Arsanis, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Departure of Directors or Certain - March 20, 2020
Entry into a Material Definitive - March 17, 2020
Securities to be offered to employees in employee benefit plans - March 13, 2020
Arsanis, Inc. Just Filed Its Annual Report: Net Loss per Share— ... - March 12, 2020
Arsanis: X4 Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full Year 2019 Financial Results - March 12, 2020

Auto Refresh

Feedback